What a Coverage Analysis Actually Decides, And Where Auditors Actually Look

THE BILLING GRID
A weekly column on research billing and coverage analysis, by Krishma Shah

A billing coordinator submits a claim for a complete blood count. The claim gets flagged. The coordinator pulls the coverage analysis, finds CBC listed as standard of care, and assumes the designation covers the claim. The auditor disagrees. The designation was correct for the screening visit. The claim was for week eight. Same procedure, different cell in the visit grid, different answer.

That scenario repeats across research billing audits more often than most site finance teams realize, because the foundational misunderstanding is structural: a Medical Coverage Analysis (MCA) does not designate procedures. It designates cells. The defensible unit of a coverage analysis is the intersection of a procedure and a visit, and every billing decision the site makes downstream has to trace back to that cell.

What the Three Designations Actually Mean

Every cell in a coverage analysis carries one of three designations. SOC, or standard of care, means the item is clinically indicated independent of the research and can be billed to Medicare or a commercial insurer when the trial qualifies under the applicable coverage framework. RES, or research-paid, means the item is a protocol requirement the sponsor has agreed to fund, and billing it to a payer is research billing fraud. NB or INV, non-billable or invoiceable, covers items that fall outside both categories and are handled separately in the site budget.

The governing federal framework for routine cost billing in clinical trials is National Coverage Determination 310.1, which allows Medicare billing for routine costs in qualifying clinical trials. A trial qualifies when it is conducted under an Investigational New Drug application and meets the NCD’s criteria for therapeutic intent and items that fall within a Medicare benefit category. When those conditions are satisfied, SOC items that would be covered outside a trial remain coverable inside one.

What NCD 310.1 does not do is make a blanket designation for a procedure across all visits. That work belongs to the coverage analysis, and it has to be done visit by visit.

The Cell Is the Argument

Consider how a CBC gets designated in a real oncology monitoring trial. At the screening visit, the hematology panel is clinically indicated to establish baseline organ function. Any oncology patient entering a new treatment regimen would receive that panel under standard clinical practice. The MCA designates the screening CBC as SOC, supported by the clinical rationale and, if it needs a coding anchor, NCD 190.15, which governs routine blood studies. The claim to Medicare is defensible because the test would have been ordered regardless of enrollment.

At week eight, the protocol adds an unscheduled safety visit that would not occur outside the trial. The patient’s disease state has not changed in a way that would independently trigger a visit. The visit exists because the protocol requires additional monitoring at that interval. The CBC drawn at that visit is a protocol-required test at a protocol-required visit. The correct designation is RES. Billing it to Medicare as SOC is billing Medicare for a sponsor obligation, which is the core fact pattern that produced the research billing enforcement actions that sites cite as cautionary examples, including the pattern from Rush University Medical Center’s 2005 settlement, where the government alleged Medicare was billed for items that were the sponsor’s responsibility to cover.

The procedure did not change. The clinical context of the visit did. That is why the cell is the argument, not the procedure row.

Where the Visit Grid Creates Audit Risk

Auditors reading an MCA are not reading it as a list of procedures. They are reading the schedule of events against the billing record and asking whether each claim maps to a cell designation that can be defended on the clinical facts of that visit. Two structural problems in coverage analysis construction expose sites to findings at that step.

The first is citation gaps on lab items. Writing that routine labs are designated SOC without a procedure-specific citation is an audit weak point. A CBC needs to reference NCD 190.15. A metabolic panel needs its own anchor. The citation is not bureaucratic formality; it is the documented clinical rationale that the designation did not require enrollment to justify. Without it, the SOC designation is an assertion, not an argument.

The second is schedule decomposition errors in imaging-heavy protocols. Some protocols describe a scan schedule as a set, for example, every eight weeks for nine cycles. When a coverage analyst builds the visit grid and decomposes that set into individual visits, the parent schedule sometimes drops out of the MCA. The result is a grid that shows one imaging designation rather than nine, and the remaining eight visits go undesignated. Billing continues. The claim goes out with no cell-level coverage determination behind it. Templates do not catch this; a human reviewer reading the protocol’s schedule of events against the visit grid has to catch it. Sites I work with that audit their MCAs against the protocol schedule of events before activation find these gaps routinely. Sites that do not find them during inspections.

Device Trials and the IDE Variable

For device trials operating under an Investigational Device Exemption, the SOC vs RES determination adds a layer. Coverage for IDE device trials depends on whether the device is designated Category A, meaning it is experimental and not covered, or Category B, meaning it has been established as safe and the question is only effectiveness. The CMS approval letter for the IDE controls that designation, and the MCA has to reflect it. A Category A device cannot be designated SOC at any visit. A Category B device may have covered routine costs for items that would be covered outside the trial. The MCA built without the IDE approval letter in hand is built on an assumption, and assumptions fail audits.

What Happens Before the Budget Arrives

One operational reality that sites often miss: the MCA is a deliverable at feasibility, before a finalized budget exists. At that stage, imaging scope and visit structure are set by protocol, and the MCA designates what is SOC and what is research-paid based on clinical rationale alone. The budget negotiation comes later. In the budget pass, the invoiceable section is reconciled against the site’s charge master, and research-paid items are priced at the greater of the sponsor rate or the charge master rate. That reconciliation only works cleanly if the MCA’s cell-level designations are accurate, because the budget is priced off of what the MCA says the sponsor owes. An MCA with designation errors produces a budget with pricing errors, and the billing team inherits both.

The MCA also sits on the site-activation critical path alongside the contract and IRB approval. A coverage analysis that has to be rebuilt after the budget is received because the initial designations were indefensible does not just create a compliance problem. It delays activation. Every day the MCA is wrong is a day the site cannot open.

Billing audits are not looking for the wrong procedure. They are looking for the wrong cell. Build the MCA accordingly.